The art of oncoimmunovaccinomics will be concisely explained herein. This scientific insight will explore its history cancer immunotherapy, the molecular basis of cancer immunotherapy, cancer immunotherapeutic approach, cancer immunosurveillance and immunoediting, the hallmarks of cancer (can be) revisited, nanotechnology-based cancer immunotherapy, immunovaccinomics, vaccinomics approach, the theory of vaccinology, adversomics, and immunogenomic perspectives.
References
[1]
Schrama, D., Reisfeld, R.A. and Becker, J.C. (2006) Antibody Targeted Drugs as Cancer Therapeutics. Nature Reviews Drug Discovery, 5, 147-159. https://doi.org/10.1038/nrd1957
[2]
Galluzzi, L., et al. (2014) Classification of Current Anticancer Immunotherapies. Oncotarget, 5, 12472.
[3]
Tokuyasu, T.A. and Huang, J.-D. (2018) A Primer on Recent Developments in Cancer Immunotherapy, with a Focus on Neoantigen Vaccines. Journal of Cancer Metastasis and Treatment, 4, 2. https://doi.org/10.20517/2394-4722.2017.52
[4]
Schirrmacher, V. (2019) From Chemotherapy to Biological Therapy: A Review of Novel Concepts to Reduce the Side Effects of Systemic Cancer Treatment. International Journal of Oncology, 54, 407-419.
[5]
Sukari, A., et al. (2016) Cancer Immunology and Immunotherapy. Anticancer Research, 36, 5593-5606. https://doi.org/10.21873/anticanres.11144
[6]
Binnewies, M., et al. (2018) Understanding the Tumor Immune Microenvironment (TIME) for Effective Therapy. Nature Medicine, 24, 541-550. https://doi.org/10.1038/s41591-018-0014-x
[7]
Nagarsheth, N., Wicha, M.S. and Zou, W. (2017) Chemokines in the Cancer Microenvironment and Their Relevance in Cancer Immunotherapy. Nature Reviews Immunology, 17, 559. https://doi.org/10.1038/nri.2017.49
[8]
Zhang, Y. and Chen, L. (2016) Classification of Advanced Human Cancers Based on Tumor Immunity in the MicroEnvironment (TIME) for Cancer Immunotherapy. JAMA Oncology, 2, 1403-1404. https://doi.org/10.1001/jamaoncol.2016.2450
[9]
Chen, D.S. and Mellman, I. (2017) Elements of Cancer Immunity and the Cancer-Immune Set Point. Nature, 541, 321-330. https://doi.org/10.1038/nature21349
[10]
Tang, T., et al. (2021) Advantages of Targeting the Tumor Immune Microenvironment over Blocking Immune Checkpoint in Cancer Immunotherapy. Signal Transduction and Targeted Therapy, 6, 1-13. https://doi.org/10.1038/s41392-020-00449-4
[11]
Teng, M.W., et al. (2015) From Mice to Humans: Developments in Cancer Immunoediting. The Journal of Clinical Investigation, 125, 3338-3346. https://doi.org/10.1172/JCI80004
[12]
Zhang, A.W., et al. (2018) Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer. Cell, 173, 1755-1769.e22.
[13]
Smyth, M.J., Dunn, G.P. and Schreiber, R.D. (2006) Cancer Immunosurveillance and Immunoediting: The Roles of Immunity in Suppressing Tumor Development and Shaping Tumor Immunogenicity. Advances in Immunology, 90, 1-50. https://doi.org/10.1016/S0065-2776(06)90001-7
[14]
Dunn, G.P., Old, L.J. and Schreiber, R.D. (2004) The Immunobiology of Cancer Immunosurveillance and Immunoediting. Immunity, 21, 137-148. https://doi.org/10.1016/j.immuni.2004.07.017
[15]
Dunn, G.P., Old, L.J. and Schreiber, R.D. (2004) The Three Es of Cancer Immunoediting. Annual Review of Immunology, 22, 329-360. https://doi.org/10.1146/annurev.immunol.22.012703.104803
[16]
Dunn, G.P., et al. (2002) Cancer Immunoediting: From Immunosurveillance to Tumor Escape. Nature Immunology, 3, 991-998. https://doi.org/10.1038/ni1102-991
[17]
Malladi, S., et al. (2016) Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT. Cell, 165, 45-60. https://doi.org/10.1016/j.cell.2016.02.025
[18]
Baxevanis, C.N. and Perez, S.A. (2015) Cancer Dormancy: A Regulatory Role for Endogenous Immunity in Establishing and Maintaining the Tumor Dormant State. Vaccines, 3, 597-619. https://doi.org/10.3390/vaccines3030597
[19]
Hanahan, D. and Weinberg, R.A. (2000) The Hallmarks of Cancer. Cell, 100, 57-70. https://doi.org/10.1016/S0092-8674(00)81683-9
[20]
Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of Cancer: The Next Generation. Cell, 144, 646-674. https://doi.org/10.1016/j.cell.2011.02.013
[21]
Fouad, Y.A. and Aanei, C. (2017) Revisiting the Hallmarks of Cancer. American Journal of Cancer Research, 7, 1016.
[22]
Carmeliet, P. and Jain, R.K. (2000) Angiogenesis in Cancer and Other Diseases. Nature, 407, 249-257. https://doi.org/10.1038/35025220
[23]
Raju, G.S.R., et al. (2019) Nanomaterials Multifunctional Behavior for Enlightened Cancer Therapeutics. Seminars in Cancer Biology, 69, 178-189.
[24]
Koshy, S.T. and Mooney, D.J. (2016) Biomaterials for Enhancing Anti-Cancer Immunity. Current Opinion in Biotechnology, 40, 1-8. https://doi.org/10.1016/j.copbio.2016.02.001
[25]
Gupta, J., Safdari, H.A. and Hoque, M. (2021) Nanoparticle Mediated Cancer Immunotherapy. Seminars in Cancer Biology, 69, 307-324. https://doi.org/10.1016/j.semcancer.2020.03.015
[26]
Pead, P.J. (2014) The Origins of Vaccination: History Is What You Remember. Journal of the Royal Society of Medicine, 107, 7. https://doi.org/10.1177/0141076813513998
[27]
Hammarsten, J.F., Tattersall, W. and Hammarsten, J. (1979) Who Discovered Smallpox Vaccination? Edward Jenner or Benjamin Jesty? Transactions of the American Clinical and Climatological Association, 90, 44.
[28]
Plotkin, S.L. and Plotkin, S.A. (2004) A Short History of Vaccination. Vaccines, 5, 1-16. https://doi.org/10.1016/B978-1-4160-3611-1.50005-2
[29]
Chen, Z., et al. (2021) Identification of COVID-19 Subtypes Based on Immunogenomic Profiling. International Immunopharmacology, 96, Article ID: 107615. https://doi.org/10.1016/j.intimp.2021.107615
[30]
Wang, Q., et al. (2021) Immunogenomic Identification for Predicting the Prognosis of Cervical Cancer Patients. International Journal of Molecular Sciences, 22, 2442. https://doi.org/10.3390/ijms22052442
[31]
Higdon, R., et al. (2017) Integrated Proteomic and Transcriptomic-Based Approaches to Identifying Signature Biomarkers and Pathways for Elucidation of Daoy and UW228 Subtypes. Proteomes, 5, 5. https://doi.org/10.3390/proteomes5010005
[32]
Haralambieva, I.H. and Poland, G.A. (2010) Vaccinomics, Predictive Vaccinology and the Future of Vaccine Development. Future Microbiology, 5, 1757-1760. https://doi.org/10.2217/fmb.10.146
[33]
Omersel, J. and Karas Kuželički, N. (2020) Vaccinomics and Adversomics in the Era of Precision Medicine: A Review Based on HBV, MMR, HPV, and COVID-19 Vaccines. Journal of Clinical Medicine, 9, 3561. https://doi.org/10.3390/jcm9113561
[34]
de la Fuente, J., et al. (2020) A Quantum Vaccinomics Approach to Vaccine Development. The Cuban Scientist, 1, 25-26.
[35]
Poland, G.A., Ovsyannikova, I.G. and Kennedy, R.B. (2018) Personalized Vaccinology: A Review. Vaccine, 36, 5350-5357. https://doi.org/10.1016/j.vaccine.2017.07.062
[36]
Poland, G.A., et al. (2016) Vaccinology in the Third Millennium: Scientific and Social Challenges. Current Opinion in Virology, 17, 116-125. https://doi.org/10.1016/j.coviro.2016.03.003
[37]
Verbeek, N.E., et al. (2014) Etiologies for Seizures around the Time of Vaccination. Pediatrics, 134, 658-666. https://doi.org/10.1542/peds.2014-0690
[38]
Li, X., et al. (2018) The Influence of Vaccine on Febrile Seizure. Current Neuropharmacology, 16, 59-65. https://doi.org/10.2174/1570159X15666170726115639
[39]
Trein, P. and Wagner, J. (2021) Governing Personalized Health: A Scoping Review. Frontiers in Genetics, 12, 513. https://doi.org/10.3389/fgene.2021.650504
[40]
Gerber, J.E. (2020) Characterization of Current and Future Vaccination Challenges in the United States: Influenza and the Policy Implications of Vaccinomics. Johns Hopkins University, Baltimore.
[41]
Kawai, T. and Akira, S. (2010) The Role of Pattern-Recognition Receptors in Innate Immunity: Update on Toll-Like Receptors. Nature Immunology, 11, 373. https://doi.org/10.1038/ni.1863
[42]
Olive, C. (2012) Pattern Recognition Receptors: Sentinels in Innate Immunity and Targets of New Vaccine Adjuvants. Expert Review of Vaccines, 11, 237-256. https://doi.org/10.1586/erv.11.189
[43]
Werling, D., Piercy, J. and Coffey, T.J. (2006) Expression of TOLL-Like Receptors (TLR) by Bovine Antigen-Presenting Cells—Potential Role in Pathogen Discrimination? Veterinary Immunology and Immunopathology, 112, 2-11. https://doi.org/10.1016/j.vetimm.2006.03.007
[44]
Buonaguro, L. and Pulendran, B. (2011) Immunogenomics and Systems Biology of Vaccines. Immunological Reviews, 239, 197-208. https://doi.org/10.1111/j.1600-065X.2010.00971.x
[45]
Bose, D. (2017) Tat-Independent Lentivirus Genomes for Vaccination and Host/ Pathogen Interaction Studies. Université Grenoble Alpes, Saint-Martin-d’Hères.
[46]
Kreileder, M., et al. (2020) Signaling Dynamics Regulating Crosstalks between T-Cell Activation and Immune Checkpoints. Trends in Cell Biology, 31, 224-235. https://doi.org/10.1016/j.tcb.2020.12.001
[47]
Kennedy, R.B., et al. (2020) Current Challenges in Vaccinology. Frontiers in Immunology, 11, 1181. https://doi.org/10.3389/fimmu.2020.01181
[48]
Gerber, J.E., et al. (2021) Ethical and Policy Implications of Vaccinomics in the United States: Community Members’ Perspectives. Human Vaccines & Immunotherapeutics, 1-12.
[49]
Anurogo, D., Parikesit A.D. and Ikrar, T. (2019) LncRNAs in CONDBITs Perspectives, from Genetics towards Theranostics (LncRNAs Dalam Perspektif CONDBITs, Dari Genetik ke Theranostik). Malaysian Journal of Health Sciences/Jurnal Sains Kesihatan Malaysia, 17, 1-16. https://doi.org/10.17576/jskm-2019-1702-01
